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Treatment with the second and third generation BCR-ABL1 tyrosine kinase inhibitors (TKIs) 
increases cardiovascular risk in chronic myeloid leukemia (CML) patients. We investigated the 
vascular adverse effects of three generations of TKIs in a translational model for atherosclerosis, 
the APOE*3Leiden.CETP mouse. Mice were treated for sixteen weeks with imatinib (150 
mg/kg BID), nilotinib (10 and 30 mg/kg QD) or ponatinib (3 and 10 mg/kg QD), giving similar 
drug exposures as in CML-patients. Cardiovascular risk factors were analyzed longitudinally, 
and histopathological analysis of atherosclerosis and transcriptome analysis of the liver 
was performed. Imatinib and ponatinib decreased plasma cholesterol (imatinib, −69%, p 
< 0.001; ponatinib 3 mg/kg, −37%, p < 0.001; ponatinib 10 mg/kg−44%, p < 0.001) and 
atherosclerotic lesion area (imatinib, −78%, p < 0.001; ponatinib 3 mg/kg, −52%, p = 0.002; 
ponatinib 10 mg/kg, −48%, p = 0.006), which were not affected by nilotinib. In addition, 
imatinib increased plaque stability. Gene expression and pathway analysis demonstrated 
that ponatinib enhanced the mRNA expression of coagulation factors of both the contact 
activation (intrinsic) and tissue factor (extrinsic) pathways. In line with this, ponatinib enhanced 
plasma levels of FVII, whereas nilotinib increased plasma FVIIa activity. While imatinib showed 
a beneficial cardiovascular risk profile, nilotinib and ponatinib increased the cardiovascular 
risk through induction of a pro-thrombotic state.
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inTrODucTiOn
Chronic myeloid leukemia (CML) is a myeloproliferative 
neoplasm caused by a translocation of the chromosomes 9 
and 22 that results in formation of the Bcr-Abl1 oncogene (1) 
and a constitutively active c-Abl kinase domain, which drives 
uncontrolled cell growth and tumorigenesis.
Patients with CML are treated with specific tyrosine kinase 
inhibitors (TKIs). The first-line TKI imatinib is widely used and 
has proven to be successful in the treatment of CML. However, 
relapses are seen in up to 17% of patients treated with imatinib 
(2) due to amplification and mutations in the Bcr-Abl1 gene (3) 
that lead to imatinib resistance. The second and third generation 
TKIs, nilotinib and ponatinib among others, are effective against 
these mutations (3), and promising results have been found 
in relapsed patients (4). Unfortunately, side effects have been 
reported in patients receiving these TKIs including myocardial 
infarction and progressive arterial occlusive disease (PAOD) (5–
7). As a result, ponatinib was temporarily removed from the US 
market, and was later reintroduced for the treatment of patients 
with T315I-positive CML or those in whom no other TKI was 
indicated.
Since the first reports of vascular adverse effects (VAEs), 
many authors related the adverse effects of TKI treatment 
to atherosclerosis and abnormal platelet function (4, 7–9). 
However, it is still unclear whether the side effects are caused 
by enhanced vascular inflammation and endothelial dysfunction, 
atherosclerosis development, increased thrombotic activity 
per se, or a combination of these processes. Furthermore, 
the underlying disease has been reported to affect metabolic 
parameters (10) and coagulation (11), which may interfere 
with the onset of the side-effects upon treatment. Therefore, 
to elucidate the role of TKI treatment on VAE’s independently 
of a background of leukemia, we performed a detailed 
experimental study in healthy pro-atherogenic mice. The aim 
of this study was to assess the (cardio)vascular side effects 
of the second and third generation of TKIs, nilotinib and 
ponatinib, and to compare their effects to the first generation TKI 
imatinib.
In this study, we used the APOE*3Leiden.CETP mouse as a 
well-established model for dyslipidemia and atherosclerosis, 
with a human-like lipoprotein metabolism and atherosclerosis 
development (See Supplemental material online for more detailed 
information on the background of the APOE*3Leiden.CETP 
mice and their response to hypolipidemic drugs; Data Sheet S1). 
These mice show a human-like response to all lipid-modulating 
interventions that are being used in the clinic (12–18) and have 
been used previously to investigate the underlying mechanism of 
cardiovascular safety issues (19).
We found that imatinib and ponatinib decreased plasma 
cholesterol, which was associated with decreased atherosclerosis 
development. Gene expression and pathway analysis demonstrated 
adverse alterations in genes involved in coagulation which were in 
line with increased plasma levels of FVII and FVIIa by ponatinib 
and nilotinib respectively, pointing towards thrombosis instead of 
atherosclerosis as inducer of the VAEs.
MaTerials anD MeThODs
animals
Female APOE*3Leiden.CETP transgenic mice (9 to 14 weeks 
of age) from the SPF breeding stock at TNO-Metabolic Health 
Research (TNO-Leiden) were used in this study. Females were used 
because they are more responsive to dietary cholesterol and fat than 
males. APOE*3Leiden females have a higher VLDL production 
(20) than males resulting in higher plasma total cholesterol (TC) 
and triglyceride (TG) levels and more pronounced development 
of atherosclerosis (21, 22). During the study, mice were housed 
under standard conditions with a 12 h light-dark cycle and had free 
access to food and water. Body weight, food intake and clinical signs 
of behavior were monitored regularly during the study. Animal 
experiments were approved by the Institutional Animal Care and 
Use Committee of The Netherlands Organization for Applied 
Research under registration number 3557.
experimental Design and analyses
Mice were fed a semi-synthetic diet, containing saturated fat 
from 15% (w/w) cacao butter and 0.15% cholesterol (Western-
type diet [WTD]; Hope Farms, Woerden, The Netherlands). All 
studies started after a run-in period of 3 weeks on WTD, which 
is designated as T = 0 weeks/baseline, after which mice were 
matched into groups based on body weight, total cholesterol, 
plasma triglycerides and age. For the pharmacokinetic (PK) 
study, mice were randomized in 3 groups (n = 9 per group) and 
received a single oral gavage with imatinib (100 mg/kg), nilotinib 
(50 mg/kg) or ponatinib (5 mg/kg). At 0.5, 1 and 2 h after oral 
gavage, blood was sampled from 3 mice per group per time point, 
and at 4, 7 and 24 h blood was collected by heart puncture after 
sacrifice. For the (cardio)vascular risk factor andatherosclerosis 
study, mice were randomized in 6 groups (n = 15 per group, n = 
20 in control group) and received, based on the results of the PK 
study, a once-daily oral gavage with nilotinib (10 or 30 mg/kg), 
ponatinib (3 or 10 mg/kg), or a twice-daily gavage with imatinib 
(150 mg/kg). The TKIs were suspended in 5% carboxymethyl 
cellulose and all mice except the imatinib group received a 
second oral gavage with the vehicle alone (5% carboxymethyl 
cellulose). The TKIs were purchased at LC laboratories, Woburn 
(MA), USA. After 12 weeks 5 mice of the control group were 
sacrificed to asses atherosclerosis development and to determine 
the end-point of the study. After sixteen weeks of treatment all 
animals were sacrificed by CO2 inhalation. Plasma cholesterol, 
triglycerides, HDL-C, lipoprotein profiles, SAA, E-selectin and 
MCP-1, aspartate transaminase (AST) and alanine transaminase 
(ALT) were measured throughout the study. Blood pressure 
was measured at 2 and 15 weeks of treatment. Measurement of 
hepatic lipid and protein content; protein and albumin content in 
broncho-alveolar lavage (BAL) fluid; urinary albumin/creatinine 
levels; and histology of lung and hearts was performed at 16 
weeks. Total FVII coagulant activity was measured at 4 and 12 
weeks and FVIIa activity at 4 weeks. Gene expression analysis 
using Next Generation Sequencing with the Illumina Nextseq 
500 and subsequent pathway analysis of liver of 8 mice per group 
was performed following established protocols (23, 24).
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statistical analysis
Significance of differences between the groups was calculated in 
SPSS 22.0 for Windows. Normally distributed data was tested 
parametrically using a one-way ANOVA for multiple comparisons 
with a Dunnett’s post-hoc test. Non-parametric data were compared 
separately with a Mann-Whitney U test with adjusted rejection 
criteria using a Bonferroni-Holm correction. Correlations between 
lesion size (after square root transformation) and cholesterol 
exposure were calculated with a Pearson’s correlation test. All 
groups were compared with the control group. Values are presented 
as means ± SD and p-values < 0.05 were considered statistically 
significant.
For a more detailed description of the applied methods, please 
see the Supplementary material online (Data Sheet S1).
resulTs
PK analysis and Plasma Drug 
concentrations
Pharmacokinetic analysis was performed after a single dose of 
imatinib (100 mg/kg), nilotinib (50 mg/kg) or ponatinib (5 mg/kg) 
(Table 1) and based on these results the doses for the atherosclerosis 
study were adjusted to twice daily 150 mg/kg for imatinib, once 
daily 10 or 30 mg/kg for nilotinib and once daily 3 or 10 mg/kg for 
ponatinib. The relatively high dose of imatinib needed to achieve 
plasma concentrations comparable to those in CML-patients was 
due to the short half-life of the drug in mice and is in line with 
previous reports (29). Drug exposure after repeated dosing was 
measured in sacrifice plasma and calculated AUCs were similar to 
those in CML-patients for imatinib and the low doses of nilotinib 
and ponatinib (Table 1).
safety aspects of Treatments with TKis
No clinical signs of deviant behavior and no effects on body weight 
and food intake were noted in any treatment group as compared 
with control. Plasma ALT and AST, measured at the start and after 
16 weeks of treatment, showed no aberrant results (Table S1; Data 
Sheet S1). The number of circulating peripheral blood mononuclear 
cells (PBMC’s) in the blood as measured by fluorescence-activated 
cell sorting (FACS) analysis at 12 weeks (Table S2; Data Sheet S1) 
was reduced by imatinib (−42%, p = 0.006) and by the high-dose 
ponatinib (−44%, p = 0.003). In addition, imatinib and the high doses 
of nilotinib and ponatinib decreased pro-inflammatory Ly6Chigh 
monocytes, all consistent with the mode of action of TKIs. Two mice 
(ponatinib 3 mg/kg) died during blood pressure measurements at 
t = 15 weeks, and one mouse (nilotinib 30 mg/kg) was excluded 
from atherosclerosis measurement due to deviating heart anatomy.
(cardio) Vascular risk Factors
Imatinib and Ponatinib Reduce Plasma Cholesterol 
Levels
As dyslipidemia is a major risk factor for cardiovascular disease, we 
measured plasma cholesterol and triglyceride levels throughout the 
study, and HDL-C at the end point. The Western-type diet resulted 
in an average plasma cholesterol of 17.3 ± 3.5 mmol/L, triglycerides 
of 3.3 ± 1.0 mmol/L, and an HDL-C level of 1.4 ± 0.2 mmol/L in 
the control group. When compared to the control group, imatinib 
reduced average cholesterol and triglyceride levels by 69% (p < 
0.001) and 36% (p = 0.019), respectively. Ponatinib decreased 
cholesterol levels by 37% (3 mg/kg, p < 0.001) and 44% (10 mg/
kg, p < 0.001), whereas nilotinib had no significant effect on plasma 
lipid levels (Figure 1A–D). At 16 weeks of treatment, HDL-C was 
decreased by ponatinib in both the low (−30%, p = 0.003) and high 
(−25%, p = 0.016) dose. The reduction of plasma cholesterol by 
imatinib and ponatinib was mainly confined to VLDL-LDL (i.e., 
non-HDL) (Figure 1C).
TaBle 1 |  Pharmacokinetics of imatinib, nilotinib and ponatinib in APOE*3Leiden.CETP mice and CML-patients.
TKi aPOe*3leiden.ceTP mice cMl patients




Dose (mg/kg) subject auc0–24  
(µg/ml*h)
reference
imatinib Single 100 2.28 5.29 32.79 Day 1, BID 400 CML-patients 36.2 ± 7.4 (25)
Repeated 
dose, BID
150 2.47 11.07 78.13 Steady state, BID 400 CML-patients 68.4 ± 29.8 (25)
nilotinib Single 50 3.26 10.97 117.49 Single, QD 400 Healthy 
subjects
14.7 ± 5.0 (26)
Repeated 
dose, QD
10 3.17 2.30 24.60
Repeated dose, QD 400–1,200 CML-patients 36.0 ± 11.8 (26)
Repeated 
dose, QD
30 3.17 6.89 73.81
Ponatinib Single 5 8.00 0.19 3.24 Single, QD 60 CML-patients 0.7 ± 0.4 (27)
Repeated 
dose, QD
3 6.72 0.14 2.43
Repeated dose, QD 15–60 CML-patients 1.3 (28)Repeated 
dose, QD
10 6.73 0.46 8.11
Tmax, Cmax and AUC0–24 were calculated after a single dose or after 16 weeks of treatment (repeated dose) for imatinib, nilotinib and ponatinib and compared with plasma 
concentrations in CML patients. AUC, area under the curve; BID, twice a day; CML, chronic myoloid leukemia; QD, once a day. Data are presented as means (APOE*3Leiden.CETP 
mice) and means ± SD (CML-patients), unless SD was not given in the reports.
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These findings show that imatinib decreases plasma cholesterol 
and triglyceride levels in APOE*3Leiden.CETP mice, which is 
consistent with the cholesterol-lowering effect observed in patients 
(30–33).
Ponatinib and Imatinib Decrease Hepatic Lipid Content
Liver lipid storage may give insight into how lipid metabolism is 
affected by imatinib and ponatinib. Therefore, hepatic lipid content 
was measured by HPTLC. Free cholesterol content was decreased by 
10 mg/kg ponatinib (−21%, p = 0.007) (Figure 2A), cholesterol ester 
content was decreased by imatinib (−30%, p = 0.001) and by both the 
low (−49%, p < 0.001) and high (−61%, p < 0.001) dose of ponatinib 
(Figure 2B). Triglyceride content was decreased by the low (−32%, p 
= 0.048) and high (−43%, p = 0.005) dose of ponatinib (Figure 2C). 
These data point to a shortage of cholesterol in the liver and suggest 
that not cholesterol clearance, but VLDL production and/or intestinal 
absorption of cholesterol are affected by ponatinib and imatinib.
Blood Pressure and Vascular Dysfunction
Increased blood pressure and endothelial activation may lead to 
vascular dysfunction and atherosclerosis. Systolic blood pressure 
(SBP), measured after 2 and 15 weeks of treatment, was 91 ± 
7 and 86 ± 5 mmHg, respectively, in the control group, and 
heart rate was 726 ± 46 and 716 ± 29 beats per minute. SBP and 
heart rate were not affected by imatinib, nilotinib or ponatinib 
treatment. As markers of vascular integrity and leakage or edema 
formation, we evaluated lung histology, determined the wet/dry 
weight ratio of the lungs and measured the amount of protein in 
the BAL fluid. None of the anti-CML drugs showed significant 
effects on histology and wet/dry weight ratio (data not shown), 
and ponatinib decreased the amount of protein in BAL fluid 
by 51% (3 mg/kg, p = 0.029) and by 47% (10 mg/kg, p = 0.041) 
(Figure S1A; Data Sheet S1). In contrast, ponatinib increased the 
urinary albumin/creatinine ratio (approximately 13-fold, N.S.), 
mainly due to 3 mice with very high levels of urinary albumin 
(Figure S1B; Data Sheet S1).
These data indicate that the anti-CML drugs did not cause 
damage to the microvasculature in the lungs but that ponatinib 
may lead to microvascular dysfunction in the kidney.
Ponatinib Increases Plasma E-Selectin
Inflammation is widely considered as an important contributing 
factor to cardiovascular events (34). Therefore, we measured plasma 
levels of macrophage-derived chemokine monocyte chemoattractant 
protein-1 (MCP-1), the adhesion molecule E-selectin as marker 
of endothelial activation, and serum amyloid A (SAA), an acute 
phase protein mainly produced by the liver (Table 2). None of the 
inflammatory markers were significantly altered by imatinib. The 
Western-type diet increased MCP-1 relative to baseline (T = 0 weeks) 
(+126%, p = 0.015), as did nilotinib (10 mg/kg, +220%, p < 0.001; 
30 mg/kg, +160%, p < 0.001). Ponatinib increased SAA relative to 
baseline (+123%, p = 0.013), but not relative to control. In four of the 
fifteen ponatinib-treated mice, E-selectin levels were 3 to 10 times 
increased, leading to an overall increase of 161% (p < 0.001) when 
compared to control, which may point to endothelial activation 
by ponatinib. Collectively, these data confirm the safety profile of 
imatinib and suggest endothelial activation and potential endothelial 
dysfunction in some animals by ponatinib .
atherosclerosis
Imatinib and Ponatinib Reduce Lesion Size and 
Severity
Next we analyzed the effects of long-term exposure of the anti-
CML TKIs on the progression of atherosclerosis as a cardiovascular 
endpoint, as shown by representative images (Figure 3). Sixteen 
weeks of Western diet resulted in the development of 4.0 ± 0.8 
atherosclerotic lesions and 156 ± 61*1,000 µm2 lesion area per 
cross-section in the control group (Figure 4A). Approximately 55% 
of these lesions were severe (type IV–V) lesions and only 10% of the 
segments were unaffected (Figure 4B). The total number of lesions 
was not affected by any treatment (data not shown), but imatinib 
and ponatinib diminished the lesion area by 78 (p < 0.001), 52 (3 
mg/kg, p = 0.002), and 48% (10 mg/kg, p = 0.006), respectively 
(Figure 4A). In addition, the total lesion area that consisted of severe 
lesions was reduced by imatinib (−56%, p < 0.001) (Figure 4B). 
Next, we evaluated whether this anti-atherogenic effect of imatinib 
and ponatinib could be explained by the reduction in plasma 
cholesterol levels. The square root of the lesion size was positively 
correlated with plasma cholesterol exposure (mmol/L*weeks) in 
control, imatinib and high dose nilotinib and ponatinib treated 
mice (control R2 = 0.79, p = 0.001; imatinib R2 = 0.71, p = 0.003; 
ponatinib 10 mg/kg R2 = 0.79, p < 0.001; nilotinib 30 mg/kg R2 = 
0.63, p = 0.016) (Figure 5). Lesion size per cross-section was not 
Figure 1 |  Imatinib and ponatinib reduce plasma cholesterol levels and 
imatinib decreases average triglycerides. Plasma cholesterol was measured 
throughout the 16 week study (a) and average plasma cholesterol (B) and 
triglycerides (D) were calculated. Lipoprotein profiles were assessed by FPLC 
lipoprotein separation after 16 weeks of treatment (c). FPLC, Fast protein 
liquid chromatography; VLDL, very-low-density-lipoprotein; LDL, low-density-
lipoprotein; HDL, high-density-lipoprotein. *p < 0.05, **p < 0.01 ***p < 0.001. 
Data are presented as means ± SD (n = 13–15 per group).
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correlated with inflammation markers or blood pressure, indicating 
a dominant role of plasma cholesterol and cholesterol-lowering by 
the drugs in the development of atherosclerosis.
Imatinib Improves Plaque Morphology
To assess the plaque phenotype as a marker for vulnerability to 
rupture, lesion morphology was analyzed in the type IV and V 
lesions from mice treated with imatinib and the high dosages 
of nilotinib and ponatinib, as shown by representative images 
(Figure 3). The macrophage and necrosis content were quantified 
as factors that decrease plaque stability, and smooth muscle cell 
area in the cap of the lesions and collagen as factors that improve 
plaque stability (17, 35, 36) (Figure  6A). Average macrophage, 
necrotic core, collagen and smooth muscle cell content in the 
control group were 24  ±  8%, 4  ±  2%, 42  ±  10% and 4  ±  3%, 
respectively (Figure 6A). Imatinib increased the collagen content 
by 47% (62 ± 17%, p = 0.004) and tended to increase αSMC content 
(+38%, p = 0.050), resulting in an enhanced lesion stability index 
(+216%, p = 0.004) (Figure 6B). Nilotinib (10 mg/kg) decreased 
collagen content (−32%, p = 0.003), resulting in a decreased lesion 
stability index (−43%, p = 0.003). Ponatinib (3 mg/kg) decreased 
necrotic core content (−58%, p = 0.001) without affecting plaque 
stability. Collectively, these data indicate that imatinib induces a 
more stable plaque phenotype with collagen-rich lesions.
Transcriptome analysis
Ponatinib Adversely Alters Gene Expression of 
Coagulation Factors
To find early molecular signatures of other clinically relevant 
processes induced by the anti-CML drugs, gene expression and 
TaBle 2 |  Ponatinib increases markers of inflammation.








Baseline - 45 ± 23 6.8 ± 4.4 87 ± 9
Control - 102 ± 44† 10.1 ± 1.2 96 ± 18
Imatinib 150 54 ± 44 9.6 ± 0.5 71 ± 18
Nilotinib 10 144 ± 82‡ 10.6 ± 1.0 79 ± 23
30 117 ± 60‡ 10.6 ± 1.1 99 ± 17
Ponatinib 3 78 ± 29 10.4 ± 1.9 77 ± 22
10 92 ± 68 15.2 ± 21.1† 250 ± 307‡/*
Effect of imatinib, nilotinib and ponatinib on inflammatory markers as measured at 
baseline (T = 0 weeks) and after 16 weeks of treatment. MCP-1, monocyte 
chemoattractant protein-1; SAA, serum amyloid A..
*p < 0.001, as compared to control.
†p < 0.05. as compared to baseline.
‡p < 0.001 as compared to baseline. Data are presented as means ± SD (n = 8–15 per 
group).
Figure 2 |  Imatinib and ponatinib decrease hepatic lipid content. Hepatic free cholesterol (a), cholesterol ester (B) and triglyceride (c) content were measured by 
HPTLC after 16 weeks of treatment. HPTLC, high-performance thin-layer chromatography. *p < 0.05, **p < 0.01 ***p < 0.001. Data are presented as means ± SD (n 
= 8 per group).
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pathway analysis was performed in the liver as the central organ in 
lipid metabolism and synthesis of coagulation factors. To identify 
drug-specific molecular responses and overlap between the various 
treatments, the total number of differentially expressed genes (DEG) 
was assessed and a Venn-diagram was constructed comprising all 
DEG compared to control group. Both ponatinib and nilotinib 
displayed a dose-dependent increase in the total number of DEG 
as compared to control and the molecular response of the high-
dose ponatinib had more overlapping genes with imatinib than 
nilotinib (Figure S2; Data Sheet S1).
General categorization of biological functions showed that 
all anti-CML drugs affect canonical pathways associated with 
mitochondrial dysfunction and oxidative phosphorylation, most 
likely induced by oxidative stress and leading to reduced energy 
production, and processes involved in protein synthesis and cell 
growth (EIF2 signaling), confirming the target-related molecular 
responses of anti-CML drugs. ( Figure S3; Data Sheet S1).
The processes relevant to (cardio)vascular (side) effects of the 
anti-CML drugs are highlighted in Figure S4; Data Sheet S1 and 
Figure 7. Although gene expression data from the liver cannot be 
directly extrapolated to atherosclerosis signaling in the vascular wall, 
gene expression profiles of different organs have affiliation with each 
other and may be predictive for these biological processes. Therefore, 
the transcriptome data of the liver as predicting organ are given. As 
compared to the other TKI’s, imatinib showed the most pronounced 
effects on atherosclerosis signaling, with favorable regulation of 
genes involved in cell adhesion (Integrin β2 and α4, Icam1, Vcam1, 
Psgl-1), macrophage activation (Cd40, Tnfrsf14, Scara1, Nfκb), lipid 
regulation (Lpl, Apoa1, Apoa2, Apoc2, Apoc4, Pla2g7 ), inflammatory 
processes (Cd40, Nfκb, Il1a, Tnfrsf14, Icam1, Vcam1) and genes related 
to extracellular matrix modulation (Col1a2, Col3a1, Col1a1, Mmp13, 
Tgf-β) (Figure S4 A–B data; Data Sheet S1). Ponatinib showed similar 
effects, but to a lesser extent, whereas these effects were not observed 
after nilotinib treatment (Figure S4 A; Data Sheet S1).
As the site of synthesis of a large number of coagulation factors, 
the liver plays an important role in the regulation of hemostatic and 
thrombotic processes. Although all three TKIs to some extent affected 
the coagulation pathways, ponatinib had the most adverse profile 
(Figure  7). Ponatinib increased the gene expression of members 
of the intrinsic or contact activation pathway, Kng1a and Klkb1, 
mainly involved in growth of a thrombus, and of the extrinsic or 
tissue factor pathway F7, involved in initiation of thrombus formation, 
and decreased gene expression of Upa and Tpa, both involved in 
fibrinolysis. Nilotinib showed down-regulation of the expression 
of F5, F9, and Protein S, while Serpina1 (PAI-1) was up-regulated. 
Imatinib down-regulated the expression of Upa, Tpa and Protein S 
and up-regulated Serpina1 and Protein C. This analysis demonstrates 
that among the three anti-CML drugs investigated ponatinib most 
prominently induces adverse alterations in the gene expression of 
coagulation factors in both the intrinsic and extrinsic pathway, which 
may lead to a state of hypercoagulability.
coagulation
Ponatinib Increases Plasma Factor VII and Nilotinib 
Increases Factor VIIa Activity
Next, we measured total factor VII coagulant activity (FVII) and VIIa 
activity (FVIIa) in plasma. Ponatinib increased FVII after 4 weeks 
(10 mg/kg, +265%, p < 0.001) and 12 weeks of treatment (3 mg/kg, 
+28%, p = 0.07; 10 mg/kg + 82%, p < 0.001) (Figure 8A). In addition, 
nilotinib increased the activity of FVIIa at 4 weeks by 82% (30 mg/kg, 
p < 0.001) (Figure 8B). Together, these data confirm our findings on 
gene expression analysis and reveal the pro-thrombotic characteristics 
of nilotinib and ponatinib.
DiscussiOn
This is the first study that compared the effect of a first, second and 
third generation BCR-ABL1 tyrosine kinase inhibitor on (cardio)
vascular risk factors and atherosclerosis. Imatinib and ponatinib 
decreased plasma cholesterol and atherosclerosis, while nilotinib 
and ponatinib activated coagulation. The pharmacokinetic data 
we provide enabled us to use drug exposures translatable to CML-
patients and can be used to optimize future TKI research. In addition, 
we provide a robust data set obtained by gene expression and pathway 
analysis of the liver, which predicted that ponatinib may lead to a pro-
coagulant state by adversely affecting coagulation factors of both the 
contact activation (intrinsic) and tissue factor (extrinsic) pathways, 
which was confirmed by increased levels of the coagulation factor VII. 
Figure 3 |  Effect of imatinib, nilotinib and ponatinib on plaque 
composition. Representative images of HPS staining, immunostaining with 
α-actin for SMCs, Sirius red staining for collagen and immunostaining with 
Mac-3 for macrophages. The arrows depict necrotic areas, including 
cholesterol clefts. Images were taken with an Olympus BX 51 microscope 
using Olympus analySIS image processing software cell^D. Original 
magnification ×16. HPS, hematoxylin-phloxine-saffron; SMCs, smooth 
muscle cells; MAC-3, Purified anti-mouse CD107b Mac-3 Antibody.
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Figure 4 |  Imatinib and ponatinib reduce atherosclerotic progression. After 16 weeks of treatment, the total lesion area per cross-section was assessed (a). 
Lesion severity was assessed, categorized as no lesions/undiseased, mild lesions (type I-III) and severe lesions (type IV-V) and expressed as percentage of total 
lesion area. (B).  **p < 0.01 ***p < 0.001. Data are presented as means ± SD (n = 13–15 per group).
Figure 5 |  Atherosclerotic lesion area is correlated with cholesterol exposure. Correlation between cholesterol exposure (mmol/L*weeks) and the square root of 
the lesion area was calculated with a Pearsons’s correlation test (n = 13–15 per group).
8 June  2018 | Volume 5 | Article 55Frontiers in Cardiovascular Medicine | www. frontiersin. org
Pouwer et al. Cardiovascular Safety of BCR-ABL1 Inhibitors
In addition, nilotinib increased activity of FVIIa. These findings can 
be used by clinicians to carefully monitor coagulation parameters in 
CML-patients to predict risk of cardiovascular events.
The choice to perform this study in a non-leukemic mouse model 
has several reasons. First, there is, inherent to the diagnosis and 
progression of the disease, a shortage of suitable high quality plasma 
samples of CML patients collected at both baseline and follow-up 
under similar conditions. Second, CML affects both metabolic (10) 
and coagulation (11) parameters which makes it difficult to elucidate 
the role of TKI treatment on the reported VAEs independently of the 
underlying disease. Last, we were able to investigate a broad range 
of parameters, including atherosclerosis and gene expression and 
pathway analysis of the liver, which is not possible in CML-patients.
Imatinib and ponatinib, but not nilotinib, decreased plasma 
cholesterol contained in the pro-atherogenic apoB-containing 
lipoproteins. Cholesterol reduction and even normalization in 
hypercholesterolemic CML-patients is repeatedly described in 
retrospective studies with CML-patients for imatinib (30–32, 37) 
and is consistent with our findings. Data on ponatinib are scarce 
(37) and it is unclear whether nilotinib affects plasma cholesterol in 
CML-patients. Some studies reported increased plasma cholesterol (5, 
8, 33, 37), whereas others question this (38). These opposing findings 
may be explained by the response to the underlying disease. It should 
be noted that nilotinib is often prescribed as a second-line treatment 
after resistance to imatinib. Reduced caloric intake induced by the 
leukemia and increased energy requirements imposed by tumor 
growth may result in lower cholesterol levels at baseline, while a 
positive response to treatment is often accompanied by increased 
cholesterol levels in oncologic patients (39). This response-related 
cholesterol elevation may be abolished by the cholesterol-lowering 
effects of imatinib and ponatinib per se as found in our study, resulting 
in decreased (imatinib) or normalized (ponatinib) plasma cholesterol 
levels in CML patients.
Several mechanisms are involved in cholesterol homeostasis, 
including intestinal uptake, hepatic uptake and secretion as 
lipoproteins, synthesis and storage, and fecal excretion. The decreased 
hepatic lipid content in imatinib and ponatinib treated mice (Figure 2) 
points to a shortage of cholesterol in the liver and suggests that 
not lipoprotein clearance, but VLDL production and/or intestinal 
absorption of cholesterol are affected by imatinib and ponatinib. 
Figure 6 |  Imatinib increases plaque stability. Necrotic and macrophage content as pro-inflammatory factors, and αSMCs and collagen as fortifying factors, were 
determined in the severe (type IV-V) lesions and expressed as percentage of total plaque area (a). Plaque stability index was calculated (B). aSMC; α smooth 
muscle cell., **p < 0.01. Data are presented as means ± SD (n = 13–15 per group).
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Indeed, when myeloid tumor cells are treated with imatinib, de novo 
fatty acid synthesis is reduced, pointing towards decreased VLDL 
particle production (40). However, besides the shared activity of TKIs 
used for CML-treatment against the BCR-ABL1 tyrosine kinase, the 
potency and activity to affect off-target kinases differs markedly, and 
thus different processes may be involved. To our knowledge, no in 
vivo studies are available that investigated the effects of TKI treatment 
on cholesterol and lipoprotein metabolism, and functional studies 
are required.
Important observations from our study are the reduced 
development of atherosclerosis by imatinib and ponatinib which was 
correlated to decreased plasma cholesterol levels, and the increased 
plaque stability induced by imatinib, which has not been reported 
previously by others. There are no reports that describe the effect 
of ponatinib on atherosclerosis development in an animal model, 
and there are inconsistent reports on imatinib and nilotinib. In line 
with our findings, imatinib reduced atherosclerosis in STZ-induced 
diabetic ApoE−/− mice (41) and high fat fed ApoE−/− mice (42), 
though lesion reduction was independent of plasma cholesterol 
lowering and attributed to vascular wall remodeling and reduced 
inflammation. Interestingly, and in contrast with previous (41–43) 
and the present findings, Hadzijusufovic et al (43). did not find an 
effect of imatinib on atherosclerosis in ApoE−/− mice, but reported 
increased atherosclerosis by nilotinib. In addition, a direct pro-
atherogenic effect on human endothelial cells was found, as 
shown by upregulation of adhesion factors ICAM-1, E-selectin 
and VCAM-1 (44), which is in line with the increase of markers of 
endothelial activation found in CML patients treated with nilotinib 
(45). Unfortunately, no data on plasma cholesterol and markers of 
endothelial activation in the mice were provided. We do not have a 
clear explanation for the discrepancy with our findings, but the use 
of different animal models and dosages, as well as the underlying 
disease may play a role.
Ponatinib increased plasma E-selectin and urinary 
albumin:creatinin in some animals, suggesting endothelial activation 
and potential endothelial dysfunction, wherein aberrant angiogenesis 
might be involved. Indeed, an in vitro study using HUVECs 
demonstrated the potential of ponatinib to reduce endothelium 
viability, and to induce apoptosis, reduce migration, inhibit tube 
formation, and to negatively affect endothelial progenitor cell 
function, all important for angiogenesis (46). In addition, ponatinib 
reduced vWF expression on lung endothelial cells in rats (47), which 
Figure 7 |  Genes in the coagulation system regulated by imatinib, nilotinib and ponatinib. The heat map shows all significantly (<0.01) upregulated (red) and 
downregulated (green) genes involved in coagulation of mice treated with imatinib (150 mg/kg), nilotinib (30 mg/kg) or ponatinib (10 mg/kg) as compared to control 
mice (a). Imatinib regulates genes involved in anti-coagulation and fibrinolysis (B). Factor 9a and 5a were down-regulated and SERPINA1 up-regulated by nilotinib 
(c). Ponatinib showed the most adverse profile with upregulation of genes in both the contact activation and tissue factor pathway, together with downregulation of 
genes involved in fibrinolysis (D). p-values of <0.01 were used as cut-off (n = 8 per group).
10 June  2018 | Volume 5 | Article 55Frontiers in Cardiovascular Medicine | www. frontiersin. org
Pouwer et al. Cardiovascular Safety of BCR-ABL1 Inhibitors
is an interesting finding, because vWF is not only a specific marker 
for ECs, but also functions in coagulation.
Although there were no clinical signs of thrombosis or bleeding 
in our long term study, an unbiased and exploratory transcriptome 
analysis revealed that ponatinib treatment lead to a pro-thrombotic 
state by affecting important players in the activation of the coagulation 
pathway. Ponatinib increased gene expression of Klkb1, Kng1a (part 
of the intrinsic or contact activation pathway) and F7 (part of the 
extrinsic or tissue factor pathway) and decreased expression of Upa 
and Tpa, which function in resolution of thrombi by fibrinolysis. 
Consistent with the increased gene expression, plasma levels of factor 
VII were increased by 265%. Nilotinib had less pronounced effects 
on gene expression of coagulation factors but increased activity of 
FVIIa by 82%. Using a different experimental design, Alhawiti et al 
(45). recently reported that a single dose of nilotinib but not imatinib 
increased platelet aggregation and thrombus growth ex vivo and in 
vivo in mice, and increased ex vivo platelet adhesion and thrombin 
generation in CML-patients receiving nilotinib (45). On the other 
hand, Loren et al (48). demonstrated that ponatinib, but not imatinib 
and nilotinib, inhibited ex vivo human platelet activation, spreading 
and aggregation, and hypothesized that the cardiovascular events 
observed in patients treated with ponatinib may be the result of 
effects on other organs and cell types. Indeed, we show that FVII 
is involved, which is produced by the liver, and is an important 
factor in the coagulation pathway. Mice lacking FVII have delayed 
thrombus formation (49) and pharmacological doses of rFVIIa induce 
hemostasis in severe hemophilia and in non-hemophilia patients with 
profuse, heavy bleeding (50). Collectively, these data indicate that 
nilotinib and ponatinib can both potentiate a pro-thrombotic state 
via different mechanisms of action.
The presence of one or more risk factors for (cardio)-metabolic 
disease together with the increased platelet aggregation and 
increased plasma activity of factor VII/VIIa may contribute to the 
onset of thrombosis, especially when combined with increased 
levels of tissue factor (TF), which activates the tissue factor pathway 
(Figure 7). Hypercoagulability has been described in a variety of 
malignancies, including hematological malignancies (51, 52), and 
many tumor cells express high levels of TF, the primary initiator of 
the extrinsic coagulation pathway (53). Therefore, we propose that 
nilotinib and ponatinib induce (athero) thrombosis in a subgroup 
of CML-patients through a combination of (cardio)-metabolic 
risk factors, enhanced levels of TF and increased plasma levels 
of coagulation factors. Our findings can be used to develop a 
multivariate risk model for CVD in CML patients, which include 
(cardio) vascular risk factors and coagulation parameters at baseline 
and during treatment, facilitating an early detection strategy for 
patients prone to cardiovascular events, which will improve therapy 
decision and patient care.
Figure 8 |  Ponatinib increases factor VII and nilotinib increases factor VIIa activity. Factor VII was measured after 4 and 12 weeks of treatment as the percentage 
of activity in reference pooled mouse plasma (a). Factor VIIa activity was measured after 4 weeks of treatment (B). ***p < 0.001. Data are presented as means ± SD 
(n = 6–20 per group).
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